Sovereign Wealth Funds Back Gene Writing Company Tessera Therapeutics

Posted on 01/12/2021


Tessera Therapeutics is a Cambridge, Massachusetts-based programmable genetics startup founded by Flagship Pioneering. The genetics company raised US$ 230 million in Series B funding from Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, and the Qatar Investment Authority (QIA).

Tessera Therapeutics was revealed publicly in July 2020 after years being incubated within Flagship Labs.

Gene Writing is a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. By changing any base pair to another, making small insertions or deletions, and writing entire genes into the genome, Gene Writing unlocks the potential to cure genetic diseases and create life-changing therapeutics in cardiovascular, oncological, neurodegenerative, and infectious diseases.

Altitude Life Science Ventures is a venture capital firm based in Kirkland, Washington that invests in early stage life science companies.

Keywords: SoftBank Group Corporation.

Get News Stories Delivered to Your Inbox